Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 9 Next >
Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian
From Bayer
Via Business Wire
Bayer Announces Full Commercialization of ThryvOn™ Technology in the U.S., a Unique Cotton Biotech Trait Set to Launch for 2023 Growing Season
From Bayer
Via Business Wire
Bayer® Aspirin Continues Long-standing Commitment to Heart Health Education, Encouraging Sports Fans to Keep Their Heart in the Game as the Official Sponsor of Fans’ Hearts
From Bayer
Via Business Wire
Phase IIb Clinical Study of Investigational Compound Elinzanetant Evaluated Efficacy and Safety in Postmenopausal Patients with Vasomotor Symptoms Study Findings Published in Menopause: The Journal of The North American Menopause Society
From Bayer
Via Business Wire
Bayer Appoints Ben Kampelman as Vice President of Communications for Crop Science North America
From Bayer
Via Business Wire
Bayer Acquires Blackford Analysis Ltd. Bolstering the Company’s Position in Digital Medical Imaging
From Bayer
Via Business Wire
Bayer to make more than $1.5 Million in Investments in STEAM Education and West Berkeley Resiliency
From Bayer
Via Business Wire
Bayer Launches Industry-First Public Database Listing Company’s Science Collaborations and Partnerships in the U.S.
From Bayer
Via Business Wire
2022 Radiological Society of North America (RSNA) Annual Meeting: Bayer to showcase product offerings and announces broadened AI offering in Radiology
From Bayer
Via Business Wire
Afrin® WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays – Because One Sick Kid Can Throw Everything Off in An Instant
From Bayer
Via Business Wire
Bayer Signs Grant Agreement to Advance Research in Non-Hormonal Contraception
From Bayer
Via Business Wire
Outside the US Bayer Extends Development Program for Investigational Product Elinzanetant With Phase III Study in Breast Cancer Patients With Vasomotor Symptoms Caused by Endocrine Therapy
From Bayer
Via Business Wire
Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology’s 2022 Kidney Week
From Bayer
Via Business Wire
Bayer’s KERENDIA® (finerenone) Recommended as Part of Comprehensive Treatment Strategy for Chronic Kidney Disease Associated With Type 2 Diabetes in Newly Published Clinical Recommendations
From Bayer
Via Business Wire
Bayer’s KERENDIA® (finerenone) Receives Grade A Recommendation as Treatment Option for Patients With Chronic Kidney Disease Associated With Type 2 Diabetes in Latest Guideline Update From American Association of Clinical Endocrinology
From Bayer
Via Business Wire
Bayer Names William Dodero New U.S. General Counsel Beginning January 2023
From Bayer
Via Business Wire
Bayer Completes Sale of Its Environmental Science Professional Business to Cinven
From Bayer
Via Business Wire
Bayer Announces Further Investment in Direct Relief Community Health Awards Program
From Bayer
Via Business Wire
Sebastian Guth Named to PharmaVoice 100 List of Most Inspiring Leaders for 2022
From Bayer
Via Business Wire
Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes
From Bayer
Via Business Wire
Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science at ESMO Congress 2022
From Bayer
Via Business Wire
Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian
From Bayer
Via Business Wire
Food Security Top Concern for Majority of Americans
From Bayer
Via Business Wire
Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian
From Bayer
Via Business Wire
FDA Label Update Reflects Bayer’s Commitment to Providing Options for Long-acting Contraception
From Bayer
Via Business Wire
Bayer Launches ForGround, a Unique Sustainable Agriculture Platform Focused on Transforming How Farmers and Companies Collaborate
From Bayer
Via Business Wire
U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
From Bayer
Via Business Wire
Stem & Root Daily Immunity Named Immune Support “Product of the Year” at NutraIngredients-USA Annual Industry Awards
From Bayer
Via Business Wire
Bayer Earns Top Score on 2022 Disability Equality Index
From Bayer
Via Business Wire
Astepro® Allergy, First and Only Steroid-Free Antihistamine Nasal Spray Now Available Over-the-Counter
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.